Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) Given Consensus Recommendation of “Hold” by Analysts

Marinus Pharmaceuticals, Inc. (NASDAQ:MRNS) has been assigned an average recommendation of “Hold” from the eleven brokerages that are covering the stock, MarketBeat Ratings reports. Eight equities research analysts have rated the stock with a hold rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month price target among brokers that have issued ratings on the stock in the last year is $4.79.

Several research analysts have recently issued reports on the stock. Royal Bank of Canada cut their target price on shares of Marinus Pharmaceuticals from $3.00 to $1.00 and set a “sector perform” rating on the stock in a report on Friday, October 25th. HC Wainwright restated a “neutral” rating and issued a $2.00 price objective on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th. JMP Securities reiterated a “market perform” rating on shares of Marinus Pharmaceuticals in a report on Thursday, October 24th. EF Hutton Acquisition Co. I upgraded Marinus Pharmaceuticals to a “strong-buy” rating in a report on Monday, September 30th. Finally, Cantor Fitzgerald reaffirmed an “overweight” rating and set a $4.00 price target on shares of Marinus Pharmaceuticals in a research report on Thursday, November 14th.

Institutional Investors Weigh In On Marinus Pharmaceuticals

Several hedge funds have recently made changes to their positions in the company. Renaissance Technologies LLC purchased a new position in Marinus Pharmaceuticals during the second quarter valued at $727,000. Acadian Asset Management LLC purchased a new position in Marinus Pharmaceuticals during the 2nd quarter valued at about $813,000. Hussman Strategic Advisors Inc. boosted its stake in Marinus Pharmaceuticals by 14.3% during the second quarter. Hussman Strategic Advisors Inc. now owns 84,000 shares of the biopharmaceutical company’s stock worth $98,000 after acquiring an additional 10,500 shares in the last quarter. Squarepoint Ops LLC purchased a new stake in Marinus Pharmaceuticals in the second quarter worth about $206,000. Finally, Point72 DIFC Ltd purchased a new stake in Marinus Pharmaceuticals in the second quarter worth about $28,000. 98.80% of the stock is currently owned by institutional investors.

Marinus Pharmaceuticals Price Performance

MRNS opened at $0.26 on Friday. The stock’s 50 day simple moving average is $0.72 and its 200 day simple moving average is $1.17. The firm has a market cap of $14.50 million, a price-to-earnings ratio of -0.11 and a beta of 1.25. Marinus Pharmaceuticals has a 1 year low of $0.25 and a 1 year high of $11.26.

About Marinus Pharmaceuticals

Marinus Pharmaceuticals, Inc, a pharmaceutical company, focuses on development and commercialization of therapeutic products for patients suffering from rare genetic epilepsies and other seizure disorders. It offers ZTALMY (ganaxolone), an oral suspension for the treatment of seizures associated with cyclin-dependent kinase-like 5 deficiency disorder for adult and pediatric patient populations in acute and chronic care, and in-patient and self-administered settings.